

WO 2004/029245

1

SEQUENCE LISTING

<110> CTT Cancer Targeting Technologies Oy

<120> Method for designing peptides

<130> 40263

<140>

<141>

<160> 24

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 1

cctttctgct cttccaacgc cgacggggct

30

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 2

actttcaacc tgcagttacc cagcgggccc

30

<210> 3

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 3

ggtggtgctc ttccaactgt acgaccatt ggggatttac tttatgttaa ctgcaggcg 59

<210> 4

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 4

cgcctgcagt taaca

15

<210> 5
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<220>
<221> misc_feature
<222> (26)..(37)
<223> v at positions 26, 28, 29, 31, 35 and 37 is a, c or g

<400> 5
gggtggttgc cttccaacgg ccgccvavva vtatvavggc tgtaccaccc atttacttta 60
tgttaactgc aggcg 75

<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 6
atcagcggcc gcgatcc 17

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 7
ttattcggtc gaaaaggatc c 21

<210> 8
<211> 4
<212> PRT
<213> Unknown Organism

<220>
<223> Description of Unknown Organism: Unknown

<400> 8
Ala Asp Gly Ala
1

<210> 9
<211> 4
<212> PRT
<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 9

Gly Ala Ala Gly

1

<210> 10

<211> 10

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 10

Cys Thr Thr His Trp Gly Phe Thr Leu Cys

1

5

10

<210> 11

<211> 10

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 11

Ser Thr Thr His Trp Gly Phe Thr Leu Ser

1

5

10

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 12

Cys Ala Thr His Trp Gly Phe Thr Leu Cys

1

5

10

<210> 13

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 13

Cys Thr Ala His Trp Gly Phe Thr Leu Cys

1

5

10

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 14
Cys Thr Thr Ala Trp Gly Phe Thr Leu Cys
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 15
Cys Thr Thr His Ala Gly Phe Thr Leu Cys
1 5 10

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 16
Cys Thr Thr His Trp Ala Phe Thr Leu Cys
1 5 10

<210> 17
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 17
Cys Thr Thr His Trp Gly Ala Thr Leu Cys
1 5 10

<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 18
Cys Thr Thr His Trp Gly Phe Ala Leu
1 5

<210> 19
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 19
Cys Thr Thr His Trp Gly Phe Ala Leu Cys
1 5 10

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
CTT-peptide with a tryptophan analogue at position 5

<220>
<221> SITE
<222> (5)
<223> Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

<400> 20
Cys Thr Thr His Xaa Gly Phe Thr Leu Cys
1 5 10

<210> 21
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control sequence

<400> 21
Cys Glu Arg Gly Gly Leu Glu Thr Ser Cys
1 5 10

<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Control sequence

<400> 22

Cys Pro Cys Phe Leu Leu Gly Cys Cys

1

5

<210> 23

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE

<222> (3)..(6)

<223> Xaa at positions 3, 4 and 6 is any hydrophilic amino acid

<220>

<223> Description of Artificial Sequence:

CTT-peptide with additional hydrophilic amino acids

<400> 23

Gly Arg Xaa Xaa Tyr Xaa Gly Cys Thr Thr His Trp Gly Phe Thr Leu

1

5

10

15

Cys

<210> 24

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

CTT-peptide with additional hydrophilic amino acids

<400> 24

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu

1

5

10

15

Cys